This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Compugen Presents Experimental Results Supporting Induction Of Immune Tolerance By CGEN-15001 Drug Candidate

In a presentation tomorrow at the Autoimmune & Inflammation Leaders’ Forum in Boston, Massachusetts, Galit Rotman, PhD, Chief Scientist of Therapeutics at Compugen Ltd. (NASDAQ: CGEN), will disclose results from an animal model study in which CGEN-15001, an Fc fusion protein drug candidate derived from a novel immune checkpoint protein discovered by Compugen, demonstrated potential to induce immune tolerance, a much desired goal for treatment of many immunological disorders. The presentation will also disclose recent positive results from a humanized animal model of psoriasis, further expanding the scope of autoimmune conditions potentially treatable by CGEN-15001.

In her presentation, Dr. Rotman will disclose results from a recently completed bone marrow transplantation study in which CGEN-15001 was highly effective in preventing graft rejection, suggesting that this drug candidate acts through an induction of immune tolerance. Establishment of immune tolerance is a key goal in the treatment of autoimmune diseases. In comparison to current therapeutic approaches that generally suppress the immune system, tolerance induction would provide a sustained resolution of the disease without compromising the immune system’s capacity to fight infections and malignancies.

The bone marrow transplantation study was performed as part of Compugen’s ongoing collaboration with Stephen Miller, Professor of microbiology-immunology at Northwestern University Feinberg School of Medicine. In this study, bone marrow cells from male mice were transplanted into female mice of the same strain, followed by monitoring of the number of male cells in their blood. In CGEN-15001 treated animals, successful engraftment of the transplanted bone marrow cells was observed, while in control animals the transplanted cells were rejected. These results suggest that treatment with CGEN-15001 induces immune tolerance towards the transplanted cells. Additional data will also be presented for CGEN-15001 supporting this highly desired mechanism of action in type 1 diabetes and multiple sclerosis animal models.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs